ClinVar Miner

Submissions for variant NM_000321.3(RB1):c.1215+1G>A

dbSNP: rs587776783
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Genetic Diagnostic Laboratory, University of Pennsylvania School of Medicine RCV000114724 SCV000087351 pathogenic Retinoblastoma 2024-05-20 criteria provided, single submitter clinical testing Case and Pedigree Information: BILATERAL CASES:20, UNILATERAL CASES:3, TOTAL CASES:23, PEDIGREES:22. ACMG Codes Applied:PVS1, PM2, PS4S
Ambry Genetics RCV000492136 SCV000580776 pathogenic Hereditary cancer-predisposing syndrome 2023-08-03 criteria provided, single submitter clinical testing The c.1215+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 12 of the RB1 gene. This alteration has been reported as a germline mutation in multiple families affected with bilateral and/or unilateral retinoblastoma (Richter S et al. Am. J. Hum. Genet. 2003 Feb;72(2):253-69; Kiran V et al. Hum. Mutat. 2003 Oct;22(4):339; Houdayer C et al. Hum. Mutat. 2004 Feb;23(2):193-202; Alonso J et al. Hum. Mutat. 2005 Jan;25(1):99; Sivakumaran T et al. Hum. Mutat. 2005 Apr;25(4):396-409; Nichols K et al. Hum. Mutat. 2005 Jun;25(6):566-74; Taylor M et al. Hum. Mutat. 2007 Mar;28(3):284-93; Abouzeid H et al. Mol. Vis. 2007 Sep;13:1740-5). Analysis of RNA from an individual with bilateral retinoblastoma carrying c.1215+1G>A demonstrated that this mutation results in the skipping of coding exon 12, leading to a frameshift and a predicted alternate stop codon (Zhang K et al. Hum. Mutat. 2008 Apr;29(4):475-84). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Of note, this alteration is also designated as c.1353+1G>A, IVS12+1G>A and g.70330G>A in published literature. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation.
Invitae RCV000114724 SCV000629273 pathogenic Retinoblastoma 2023-10-08 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 12 of the RB1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with retinoblastoma (PMID: 2601691, 12541220, 16463005, 26396485, 27582626). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 126832). Studies have shown that disruption of this splice site results in skipping of exon 12 and introduces a premature termination codon (PMID: 2601691). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic.
St. Jude Molecular Pathology, St. Jude Children's Research Hospital RCV000114724 SCV000853203 uncertain significance Retinoblastoma 2023-02-02 criteria provided, single submitter clinical testing The RB1 c.1215+1G>A intronic change results in a G to A substitution at the +1 position of intron 12 of the RB1 gene. This variant results in skipping of exon 12 resulting in nonsense-mediated decay or an abnormal protein product (PVS1). This variant has been identified in individuals with a personal and/or family history of retinoblastoma (PMID: 2601691, 12541220, 29489754, 29568217, 33456302, 34277001, internal data) and osteosarcoma (PMID: 34308366). This variant is absent in gnomAD v2.1.1 ( In summary, this variant meets criteria to be classified as pathogenic.
Fulgent Genetics, Fulgent Genetics RCV000763334 SCV000894011 pathogenic Bone osteosarcoma; Malignant tumor of urinary bladder; Small cell lung carcinoma; Retinoblastoma 2018-10-31 criteria provided, single submitter clinical testing
Genetics Program, Instituto Nacional de Cancer RCV000114724 SCV001478087 pathogenic Retinoblastoma 2020-08-20 criteria provided, single submitter research
Department of Pediatrics, Memorial Sloan Kettering Cancer Center RCV000114724 SCV001478151 pathogenic Retinoblastoma 2020-12-15 criteria provided, single submitter research
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000114724 SCV002051260 pathogenic Retinoblastoma 2021-12-03 criteria provided, single submitter clinical testing Variant summary: RB1 c.1215+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Three predict the variant abolishes a 5` splicing donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing and results in exon 12 deletion (Dunn_1989). The variant was absent in 249940 control chromosomes (gnomAD). c.1215+1G>A has been reported in the literature in multiple individuals affected with Retinoblastoma (Dunn_1989, Richter_2002, Chai_2021). These data indicate that the variant is very likely to be associated with disease. Six ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Genetics and Molecular Pathology, SA Pathology RCV000114724 SCV002761576 pathogenic Retinoblastoma 2022-06-20 criteria provided, single submitter clinical testing
Baylor Genetics RCV003460796 SCV004208491 pathogenic Malignant tumor of urinary bladder 2023-10-26 criteria provided, single submitter clinical testing
OMIM RCV000114724 SCV000034201 pathogenic Retinoblastoma 1989-11-01 no assertion criteria provided literature only
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan RCV000114724 SCV001432966 pathogenic Retinoblastoma 2019-10-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.